Vero Biotech’s Tankless Nitric Oxide System Approved for Neonates

The FDA has approved Vero Biotech’s third-generation tankless Genosyl nitric oxide delivery system to improve oxygenation in neonates with hypoxic respiratory failure and pulmonary hypertension.

The updated system uses two disposable cassettes instead of tanks and features an adaptive sensor designed to more quickly achieve the desired dose.

The system automatically switches from one depleted cassette to the second full cassette, so users do not have to switch them manually.

Atlanta, Ga.-based Vero Biotech is focused on developing innovative technologies for inhaled nitric oxide delivery in acute care hospitals and other settings.